Feng FY - Search Results

1

An Expert Review on the Combination of Relugolix With Definitive Radiation Therapy for Prostate Cancer.

Roy S, Zaorsky NG, Bagshaw HP, Berlin A, Tree A, Turner S, Koontz B, Nguyen P, Chen R, Dess RT, Jackson WC, Kishan AU, Stish B, Nagar H, Posadas E, Tran PT, Solanki A, Shore ND, Guo G, Ponsky L, Shoag JE, Morgans AK, Garcia JA, Showalter TN, Feng FY, Spratt DE. Roy S, et al. Among authors: feng fy. Int J Radiat Oncol Biol Phys. 2022 Jun 1;113(2):278-289. doi: 10.1016/j.ijrobp.2021.12.005. Epub 2021 Dec 17. Int J Radiat Oncol Biol Phys. 2022. PMID: 34923058 Review.

2

Intensity-modulated radiotherapy of head and neck cancer aiming to reduce dysphagia: early dose-effect relationships for the swallowing structures.

Feng FY, Kim HM, Lyden TH, Haxer MJ, Feng M, Worden FP, Chepeha DB, Eisbruch A. Feng FY, et al. Among authors: feng m. Int J Radiat Oncol Biol Phys. 2007 Aug 1;68(5):1289-98. doi: 10.1016/j.ijrobp.2007.02.049. Epub 2007 Jun 7. Int J Radiat Oncol Biol Phys. 2007. PMID: 17560051 Clinical Trial.

3

Evaluating and reporting dysphagia in trials of chemoirradiation for head-and-neck cancer.

Gluck I, Feng FY, Lyden T, Haxer M, Worden F, Chepeha DB, Eisbruch A. Gluck I, et al. Among authors: feng fy. Int J Radiat Oncol Biol Phys. 2010 Jul 1;77(3):727-33. doi: 10.1016/j.ijrobp.2009.05.049. Epub 2009 Sep 23. Int J Radiat Oncol Biol Phys. 2010. PMID: 19783380 Free PMC article.

4

The percent of positive biopsy cores improves prediction of prostate cancer-specific death in patients treated with dose-escalated radiotherapy.

Qian Y, Feng FY, Halverson S, Blas K, Sandler HM, Hamstra DA. Qian Y, et al. Among authors: feng fy. Int J Radiat Oncol Biol Phys. 2011 Nov 1;81(3):e135-42. doi: 10.1016/j.ijrobp.2011.01.007. Epub 2011 Feb 23. Int J Radiat Oncol Biol Phys. 2011. PMID: 21345617

5

Gleason pattern 5 is the greatest risk factor for clinical failure and death from prostate cancer after dose-escalated radiation therapy and hormonal ablation.

Sabolch A, Feng FY, Daignault-Newton S, Halverson S, Blas K, Phelps L, Olson KB, Sandler HM, Hamstra DA. Sabolch A, et al. Among authors: feng fy. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e351-60. doi: 10.1016/j.ijrobp.2011.01.063. Epub 2011 Apr 13. Int J Radiat Oncol Biol Phys. 2011. PMID: 21493015

6

Continued benefit to androgen deprivation therapy for prostate cancer patients treated with dose-escalated radiation therapy across multiple definitions of high-risk disease.

Stenmark MH, Blas K, Halverson S, Sandler HM, Feng FY, Hamstra DA. Stenmark MH, et al. Among authors: feng fy. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e335-44. doi: 10.1016/j.ijrobp.2011.04.037. Epub 2011 Jun 7. Int J Radiat Oncol Biol Phys. 2011. PMID: 21645976

7

The Cancer of the Prostate Risk Assessment (CAPRA) in patients treated with external beam radiation therapy: evaluation and optimization in patients at higher risk of relapse.

Halverson S, Schipper M, Blas K, Lee V, Sabolch A, Olson K, Sandler HM, Feng FY, Hamstra DA. Halverson S, et al. Among authors: feng fy. Radiother Oncol. 2011 Dec;101(3):513-20. doi: 10.1016/j.radonc.2011.05.080. Epub 2011 Jun 22. Radiother Oncol. 2011. PMID: 21703711

8

Perineural invasion predicts increased recurrence, metastasis, and death from prostate cancer following treatment with dose-escalated radiation therapy.

Feng FY, Qian Y, Stenmark MH, Halverson S, Blas K, Vance S, Sandler HM, Hamstra DA. Feng FY, et al. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e361-7. doi: 10.1016/j.ijrobp.2011.04.048. Epub 2011 Aug 4. Int J Radiat Oncol Biol Phys. 2011. PMID: 21820250

9

Percentage of cancer volume in biopsy cores is prognostic for prostate cancer death and overall survival in patients treated with dose-escalated external beam radiotherapy.

Vance SM, Stenmark MH, Blas K, Halverson S, Hamstra DA, Feng FY. Vance SM, et al. Among authors: feng fy. Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):940-6. doi: 10.1016/j.ijrobp.2011.09.005. Epub 2011 Nov 4. Int J Radiat Oncol Biol Phys. 2012. PMID: 22056069

10

Radiation therapy with full-dose gemcitabine and oxaliplatin for unresectable pancreatic cancer.

Hunter KU, Feng FY, Griffith KA, Francis IR, Lawrence TS, Desai S, Murphy JD, Zalupski MM, Ben-Josef E. Hunter KU, et al. Among authors: feng fy. Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):921-6. doi: 10.1016/j.ijrobp.2011.08.022. Epub 2011 Dec 28. Int J Radiat Oncol Biol Phys. 2012. PMID: 22208966 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

528 results

Search Page

Filters